Soy consumption is up 14 percent since 2011,26 yet confusion lingers over soy’s role in everything from human health to food production. To clear up misperceptions, the United Soybean Board (USB) busts five common soy myths with science-backed facts on SoyConnection.com/soy-wisdom.
1) Eating soy does not increase breast cancer risk.
Clinical studies show soy isoflavone exposure does not adversely affect breast tissue as assessed by markers of breast cancer risk, such as breast cell proliferation.1–7 The American Institute for Cancer Research and the American Cancer Society say that women who have been diagnosed with breast cancer can safely consume soyfoods. In fact, the World Cancer Research Fund International has identified a link between soy consumption and an improved survival of breast cancer patients.8-9
“Not only does evidence indicate soyfoods may benefit women with breast cancer, but consuming soy when young helps prevent the onset of this disease later in life27-30,” stated Mark Messina, Ph.D., who has dedicated the past 30 years to understanding the health effects of soyfoods.
To view the multimedia release go to:
http://www.multivu.com/players/English/7877951-united-soybean-board-top-soy-myths/
Johnson & Johnson today honors the winners of the 2012 Dr. Paul Janssen Award for Biomedical Research in a ceremony and scientific symposium at the New York Academy of Sciences in New York, NY. Victor Ambros, Ph.D., of the University of Massachusetts Medical School, and Gary Ruvkun, Ph.D., of Massachusetts General Hospital and Harvard Medical School, received the award for their collaborative discovery of microRNAs (miRNAs) as central regulators of gene expression and development, and will share a $100,000 prize.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58019-johnson-and-johnson-jnj-2012-dr-paul-janssen-award-for-biomedical-research
Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. The test utilizes combined assays for genetic alterations and protein biomarkers and has the capacity not only to identify the presence of relatively early cancer, but also to localize the organ of origin of these cancers.
“The potential this has for pancreatic cancer is unprecedented,” says Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine, Director, Pancreatic Cyst Center of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. “We know that in 80-85 percent of pancreatic cancer cases, it’s detected too late, leaving the patient with few options. Developing a blood screening test for pancreatic cancer has been an urgent goal, because catching the disease early will be the way we get to long-term survival.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213751-lustgarten-foundation-pancreatic-cancer-blood-test/
Testfahrt mit dem neuen Golf GTI zum Wörthersee dem Mekka der GTI-Fahrer. Nahezu 1,9 Millionen Golf GTI wurden bislang im Volkswagen Werk Wolfsburg hergestellt und weltweit verkauft. Damals, 1976, als der GTI erfunden wurde, ahnte diesen Erfolg niemand. 5.000 Exemplare waren geplant, von einem Auto, das heute das erfolgreichste seiner Art auf der Welt ist. Ein Phänomen. Präziser als jeder Kompaktwagen zuvor definierte der erste Golf GTI vor 37 Jahren ein Ur-Maß der Dynamik, zudem machte der erschwingliche Volkswagen die automobile Sportlichkeit für mehr Menschen denn je erreichbar. Jetzt startet eine neue, die siebte GTI-Generation durch.
Eli Lilly and Company (NYSE: LLY) will commemorate its 140th anniversary today with activities at Lilly locations worldwide, including a ceremony to unveil a statue dedicated to founder Colonel Eli Lilly at global headquarters in Indianapolis.
Over 14 decades, the organization has contributed more than 100 medicines and significant medical advances, such as the first commercially available insulin, manufacturing and global distribution of the Salk polio vaccine and mental health breakthroughs such as anti-depressant Prozac® (fluoxetine). Today Lilly continues to progress its most robust pipeline in history with dozens of potential new medicines in mid- to late-stage development for cancer, diabetes, autoimmune disease, pain and Alzheimer’s disease.
“As Lilly celebrates 140 years, we’re keeping the vision of our founder alive – from our dedication in the lab to our impact in the community,” said John C. Lechleiter, Ph.D., Lilly chairman, president and chief executive officer, who began his career at Lilly as a chemist in 1979. “Colonel Eli Lilly started this company to put science to work fighting disease and encouraged his successors to ‘take what you find here and make it better and better.’ That vision pushes us daily to honor Colonel Lilly’s legacy and continue in our quest to discover new medicines to help make life better.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7809951-eli-lilly-and-company-140th-anniversary/
In an effort to improve outcomes for patients with some of the deadliest childhood cancers, St. Jude Children’s Research Hospital scientists have created the world’s largest collection of pediatric solid tumor samples, drug-sensitivity data and related information and have made the resource available at no charge to the global scientific community.
St. Jude and the Howard Hughes Medical Institute collaborated to create the resource, known as the Childhood Solid Tumor Network. The work is reported today as an advance online publication in the scientific journal Nature.
“Survival rates for children with recurrent solid tumors have not improved significantly in more than 20 years and remain below 30 percent,” said corresponding author Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute investigator. “This research will change that by promoting scientific collaboration to leverage the efforts of researchers worldwide to advance understanding and ultimately treatment of pediatric solid tumors.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8121952-st-jude-childrens-childhood-solid-tumor-network/
Combining their expertise in clinical trials support and cellular therapies, BloodCenter of Wisconsin (BCW) and the San Diego Blood Bank (SDBB) have created a strategic partnership to accelerate advancements in research and patient care. Together, BloodCenter of Wisconsin and San Diego Blood Bank will offer Celluvative™ – a portfolio of products and clinical trial services that will include esoteric laboratory testing, blood products for research and manufacturing applications, cell processing, and access to a broad database of diverse donors who have expressed interest in clinical trials.
“Through the strength of our partnership, we are able to offer end-to-end services to academic organizations, research institutions and other industry partners who are working to develop novel cellular therapy approaches,” said Matthew Anderson, M.D., Ph.D., medical director, BloodCenter of Wisconsin Diagnostic Laboratories. “Among other offerings, our Celluvative portfolio enables access to an extremely diverse donor database – an invaluable resource to enable advances in the area of regenerative medicine and drug discovery.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7855451-bloodcenter-sdbb-celluvative/
Bright Starts™ introduces a fun new metric, the Baby Laugh Index™, in tandem with the launch of three new toys designed to inspire laughter. The inspirations for the focus on laughter are the three new baby toys from the Bright Starts Having a Ball™ collection: 3-in-1 Step ’N; Ride Lion™, Hide ’N Spin Monkey™ and Jungle Fun Ball Climber™. Teaming up with Gina Mireault, Ph.D. professor of psychology and counseling behavior sciences at Johnson State College and researcher of humor and emotional development in children, Bright Starts seeks to emphasize the importance of laughter in infant development.
To view the multimedia assets associated with this release, please click: http://www.multivu.com/players/English/7251151-bright-starts-tm-introduces-fun-new-baby-laugh-index/
Even the panel of “odor specialists” resisted the urge to cover their noses as pungent smells emanated from the smelliest sneakers in this year’s Annual National Odor-Eaters Rotten Sneaker Contest. Ready to be judged, seven kids, ages seven to sixteen, from across the country have arrived in Montpelier today, selected as national finalists, wearing the decrepit and odorous rubber-soles that won them regional recognition.
In its 37th year, the National Odor-Eaters Rotten Sneaker Contest is the ultimate test of just how dirty and stinky sneakers can get when they’re part of an active kid’s life, going where they go, through puddles, mud and all. Sneakers are judged on the conditions of the sole, tongue, heel, toe, laces or velcro, eyelets/grommets, overall condition and most important ODOR, by a panel that includes NASA “Master Sniffer” George Aldrich, Chemical Specialist for NASA space missions, and Rachel Herz, Ph.D., a professor at Brown University and author of The Scent of Desire and That’s Disgusting.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55027-37-th-annual-odor-eaters-rotten-sneaker-contest
Regional winners of the Rotten Sneaker Contest® gathered at Ripley’s Believe It Or Not! Times Square for the 2016 national competition. Six contestants from across the country, ages seven to thirteen, went head-to head in New York City today to show off their foul smelling sneakers for a chance to win the national title. But only one pair of sneakers could be crowned the winner and they belonged to 12 year old, Mason Young-Hiss, from Berthoud, CO.
The Odor-Eaters Rotten Sneaker Contest is the ultimate test that shows how offensive kids’ sneakers can get when they are playing outdoors, splashing through puddles, slogging through mud and more. The contest has a long history (over 40 years) and kids from across the country look forward to this annual event in their hometown. Participants take pride in mucking up their shoes to stand out from their competitors to ultimately win over the judges. Sneakers are judged on the interior and exterior conditions of the shoe, and most importantly odor, by a professional panel that includes NASA “Master Sniffer” George Aldrich, Chemical Specialist for NASA space missions, and Rachel Herz, Ph.D., an expert and author on the psychology of smell. Additionally, Brittany Every, Marketing Manager of Ripley’s Believe Or Not! Times Square joined the expert judges this year. Brittany is accustomed to seeing the unexpected and unusual at Ripley’s so she was up for the task.
To view the multimedia release go to:
http://www.multivu.com/players/English/7720051-odor-eaters-rotten-sneaker-contest/
As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy.
Dr. Ohsumi was honored today during an event at the 2016 BIO International Convention in San Francisco. A video of his acceptance comments can be viewed here.
“Dr. Ohsumi’s curiosity led him to become the first person in the world to determine the molecular mechanism and regulation of autophagy, shedding light on one of the most basic functions of all living cells,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “Dr. Ohsumi’s discoveries hold promise for better understanding, preventing and treating many diseases. It is with great pleasure that we celebrate his contributions, which remind us of the innovative spirit Dr. Paul brought to the lab every day.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7856351-2016-dr-paul-janssen-award-ohsumi/
